LITMUS Molecular Design
LITMUS Molecular Design (LMD)creates and characterizes new molecular entities.
LMD's technology, LITMUS Spectral Modeling, is a patented method of accurately predicting a molecule's:
- Chemical reactivity
- Biological activity
- Receptor binding affinity
- Toxicity, carceogenicity
- Metabolism
- Absorption/through-membrane transmission,
- and chemical and physical properties,
based upon spectral information.
Developed at FDA's National Center for Toxicological Research (NCTR), LITMUS Spectral Modeling represents a "disruptive" technology which produces significantly more accurate results than Quantitative Structure Activity Relationships (QSAR) and Combinatorial Chemistry/High-Throughput Screening; currently the two most widely used methodologies. In side by side tests, LITMUS Spectral Modeling’s predictive accuracy proved to be 80-96% compared to 30-60% predictive accuracy for QSAR.
LITMUS Molecular Design’s value proposition is to enable pharmaceutical companies, chemical manufacturers, and herbicide and pesticide manufacturers to:
- Identify promising new compounds
- Predict efficacy or toxicity of new compounds
- Modify existing compounds to be more effective/less toxic
- Expedite introduction of drugs/NCEs
- Reduce time/cost of new drug/chemical development significantly
LITMUS Molecular Design is a subsidiary of LITMUS, LLC, a global technology innovation company. Our focus is on using LITMUS Spectral Modeling, the application of its patented methodology (Spectral Data Activity Relationship) to dramatically reduce the time and cost of commercializing new molecular entities. LITMUS Molecular Design provides to its customers both products and services:
- LITMUS Molecular Analysis Services (L-MAS).
- LITMUS Molecular Entity Design (L-MED).
Solutions related to undesirable and/or desirable product characteristics for customer-identified compounds (e.g., toxicity prediction/ranking, information to support modification of existing compounds to improve efficacy/reduce toxicity),
Using Spectral Modeling to design new chemical entities for out-licensing or direct sale.
LITMUS Molecular Design provides custom solutions to specific problems. LMD is customer focused, delivering products and services that exceed its customer's expectations.
For additional information, contact:
Bill Massey Ph.D. – bmassey@litmusgti.com